Innomedics

Innomedics logo

INNOMEDICS has been found since 2001 to market and distribute the highest quality of medical supplies and equipment for the betterment of human health.  Mission was started with dedicated and well trained professionals who drove it to be one of the major players in the field of specialty.  Jordan probably is the most advanced country in the region in adopting and implementing new medical technology, therefore it is becoming a referral center for patients from most countries in the region with formal agreements with Yemen, Libya, Sudan, Iraq and Algeria.  Innomedics utilize this opportunity to strengthen its position by providing clinical and technical support in addition to assisting physicians and technicians in obtaining proper training in order to enhance product familiarity and user capabilities with application ease.

 Innomedics key strategies are:

  • Successful implementation of sales and marketing plan to medical sector, in order to obtain the maximum market share.
  • Direct, continuous and professional product promotion utilizing high-tech knowledge and market research on own and competitors' products.
  • Stocking and just-in-time supplying products to the medical community at relaxed and flexible terms of sale.

Our Vision

  • Continued efforts to increase sales and market share for existing products through constant market follow-up and continuous education for physicians and other medical professionals.
  • Expanding product diversity to complement existing lines thereby strengthening and entrenching relations with clients while concentrating on state of the art medical technologies.

Contact details

Internal Medical Supplies CO.Ltd
Jabal Amman
2nd circle, Tala'at Harb
ST.11181
P.O Box 2450
Amman/ Jordan

Jabal Amman / Mr. Mohammad Al Banna
Email: m.banna@innomedicsco.com

Tel:  +962 6 4617 242
Fax:  +962 6 4617 243

Regulatory notices and product safety data

Worldwide (excluding USA)

Bead Block™ is CE marked and indicated for the treatment of a variety of hypervascular tumours (including Uterine Fibroids) and arteriovenous malformations (AVMs). For full prescribing information please refer to Bead Block instructions for use.

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). Both indications may not be available in your territory. For full prescribing information please refer to DC Bead instructions for use.

DC BeadM1™ is indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead M1 instructions for use.

USA

In the USA, Bead Block™ is indicated for the treatment of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to Bead Block USA Instructions for use.

LC Bead™ is cleared by the FDA for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to LC Bead instructions for use.

LC Bead M1™ is cleared by the FDA for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to LC Bead M1 instructions for use.

DC Bead is not currently available for sale or distribution in the USA. Both indications may not be available in your territory. 

DC Bead M1 is not currently available for sale or distributions in the USA. 

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

DC BeadM1 is primarily intended as an embolic agent to treat vessels supplying malignant colorectal cancer metastasised to the liver (mCRC). DC BeadM1 is also compatible with irinotecan, which can be loaded prior to embolisation and then, as a secondary action, elute a local, controlled and sustained dose to the mCRC after embolisation. For full prescribing information please refer to DC BeadM1 Canada Instructions for Use  

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.

Hong Kong

PRECISION Bead™ is indicated for the delivery of Doxorubicin, a chemotherapeutic agent for the treatment of malignant hypervascular tumours, where Trans Arterial Embolisation (TAE) is not contraindicated.